三阴性乳腺癌的研究进展  

Progress in the study of triple negative breast cancer

作　　者：顾军[1] 于泽平[1] 李宁[1] 

机构地区：[1]南京军区南京总医院普通外科,南京医学博士210002

出　　处：《医学研究生学报》2010年第1期105-109,共5页Journal of Medical Postgraduates

基　　金：南京军区南京总医院科研基金(2005045)

摘　　要：三阴性乳腺癌(triple negative breast cancer,TNBC)是指雌激素受体(estrogen receptor,ER)、孕激素受体(proges-terone receptor,PR)与人类表皮生长因子受体2(human epidermal growth factor receptor-type2,Her-2)均为阴性的一类乳腺癌,其具有侵袭性生物学行为及临床病理特征的一个乳腺癌亚型,与基底细胞样乳腺癌和乳腺癌易感癌基因1(breast cancer suscep-tibitity genel,BRCAI)相关性乳腺癌有一定相关性。此类型乳腺癌对常规标准治疗效果欠佳,易发生远处转移,预后较其他类型乳腺癌差。对TNBC的深入研究,将有助于人们采取有效的治疗方法来提高其疗效。Triple-negative breast cancer （TNBC） is a subgroup of breast cancers defined by a lack of the expressions of estrogen, progesterone and HER2 receptors, with more aggressive biological and clinicopathological characteristics and a close relationship with basal-like and breast cancer susceptibility gene-1 （ BRCA1 ） -related breast cancers. TNBC is insensitive to most available hormonal or standard therapeutic agents, associated with increased risk for distant metastases and with poorer prognosis than other types of breast cancer. A deeper insight into the biology of TNBC may lead to improved therapies and better clinical outcomes of the disease.

关 键 词：三阴性乳腺癌 基底细胞样乳腺癌 乳腺癌易感癌基因 预后 治疗 

分 类 号：R737.9[医药卫生—肿瘤]